Pure Monograph
Build Monograph

Bring a target. Get the molecule, and the case for it.

Ten scientific dimensions, designed from the ground up. Where the evidence to support a field doesn't exist, Pure Monograph marks the gap instead of filling it.

scroll
Illustrative readout

Ten dimensions. One refused.

A monograph marks what the record can support — and where it goes silent. Not a real program.

TARGET KRAS G12D ROUTE ORAL PATHWAY 505(b)(1) 1 FIELD REFUSED · 2 FLAGGED
01
Target & mechanismResolved

Covalent engagement at the switch-II pocket, GDP-state selective. Mutant-over-wildtype selectivity is the governing design constraint.

02
Component designResolved

Quinazoline core, acrylamide warhead, tethered piperazine linker at the solvent-exposed vector.

03
Formulation & deliveryResolved

Amorphous solid dispersion, spray-dried. BCS Class II behaviour drives the enabling-formulation requirement.

04
StabilityFlagged for review

Warhead hydrolysis predicted above pH 6. Flagged, not corrected — a design change here is a chemistry decision, not a software one.

05
Bioavailability & PKResolved

Predicted moderate oral F with CYP3A4 as the primary clearance route. Food effect anticipated.

06
Safety & toxicityFlagged for review

Off-target covalent reactivity against three cysteine-containing kinases in the screening set. Requires wet-lab confirmation before it means anything.

07
Manufacturing & costResolved

Seven linear steps, one chiral resolution. Spray-drying is the capital constraint at scale.

08
Regulatory pathwayResolved

505(b)(1) NME. No suitable reference listed drug for a bridged filing.

09
IP & noveltyData gap — refused

Applications filed within the last 18 months are unpublished and cannot be searched. A freedom-to-operate position cannot be honestly stated from the public record. Pure Monograph will not state one. Retain counsel for a formal opinion.

10
Confidence & risk flagsResolved

Stability and off-target reactivity carry forward as open items. IP position is unassessed, not clear.

TEN DIMENSIONS · SEVEN RESOLVED · TWO FLAGGED · ONE REFUSED EVERY FIELD TRACED TO SOURCE

Illustrative readout. Not a real program.

Why it's trusted

The refusal is the product.

Most systems answer everything put to them. That is the failure mode, not the feature.

01 — ENFORCED

In code, not prose

The refusal fires at the output boundary — not as a prompt instruction, not as a caveat buried in the wording. A gate that lives in the wording is a gate that eventually opens.

02 — FLAGGED

Never silently repaired

A field that looks wrong is raised for review, not quietly corrected. Quiet repair is how a plausible answer replaces a true one without anyone noticing.

03 — COST

Why it matters

A confident wrong answer wearing correct citations costs a development cycle. It is more expensive than an obvious error, because nobody catches it in review.

Also on the platform

Trial Autopsy

The other direction. Bring a terminated trial and it returns a cause of failure across six diagnostic lenses — with the counterfactual module running the design that wasn't run.

Bring it a target free.

No call, no demo booking, no sales sequence. Run one monograph and judge it on the output.

Start free